The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$20.55

Today's change+0.18 +0.88%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$20.55

Today's change+0.18 +0.88%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc up $0.18

Valeant Pharmaceuticals International Inc closed up Friday by $0.18 or 0.88% to $20.55. Over the last five days, shares have lost 10.50% and are down 85.38% for the last year to date. This security has underperformed the S&P TSX by 95.78% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward3.05×
  • Forward PEG0.18×
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$8.62
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-22.57%

Although this company's net profit margin is negative, it is above the industry average and implies that Valeant Pharmaceuticals International Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.17%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue2,4802,4202,3722,736
Total other revenue--------
Total revenue2,4802,4202,3722,736
Gross profit1,8221,7621,7422,060
Total cost of revenue658658630677
Total operating expense3,3432,3402,3052,542
Selling / general / administrative661672813743
Research & development10112410396
Depreciation / amortization807888695789
Interest expense (income), net operating--------
Unusual expense (income)1,1154442195
Other operating expenses, total1-452343
Operating income-8638166195
Interest income (expense), net non-operating-470-473-427-433
Gain (loss) on sale of assets--------
Other--------
Income before tax-1,332-377-366-240
Income after tax-1,219-304-373-362
Income tax, total-113-737122
Net income-1,218-302-374-362
Total adjustments to net income--------
Net income before extra. items-1,218-302-374-362
Minority interest12-11
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-1,218-302-374-362
Inc. avail. to common incl. extra. items-1,218-302-374-362
Diluted net income-1,218-302-374-362
Dilution adjustment--0----
Diluted weighted average shares350345345348
Diluted EPS excluding extraordinary itemsvalue per share-3.49-0.88-1.08-1.04
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.38-0.78-1.00-0.54